Education
About Us
Working with TipRanks
Follow Us
Vectus Biosystems Limited (AU:VBS)
ASX:VBS
VBS Stock Chart & Stats
AU$0.18
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.18
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.04 - AU$0.46
Previous CloseN/A
Volume32.26K
Average Volume (3M)97.35K
Market Cap
AU$8.28M
Enterprise ValueAU$7.43M
Total Cash (Recent Filing)AU$250.99K
Total Debt (Recent Filing)AU$200.00K
Price to Earnings (P/E)―
Beta0.07
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding53,433,330
10 Day Avg. Volume169,215
30 Day Avg. Volume97,349
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)-8.29
Price to Sales (P/S)4.45
P/FCF Ratio-2.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross Profit MarginA reported high gross profit margin implies the company achieves favorable unit economics on product sales. Structurally this provides room to fund R&D and sales investments, and if revenue stabilises, gross margins can support sustainable operating leverage and a clearer path to profitability.
Improving EPS TrendPositive EPS growth indicates per-share profitability is improving versus prior periods. Over a multi-month horizon this can reflect operational improvements or cost discipline that are durable if management sustains them, and it supports confidence in the company’s ability to narrow losses.
Listed On ASX (XASX)An ASX listing provides ongoing access to public capital markets and regulatory oversight, which is a durable structural advantage for a cash‑burning biotech. It enhances the company’s ability to raise equity or secure partnerships needed to fund R&D and commercialization over the coming months.
Bears Say
Sharp Revenue ContractionRevenue declined roughly 46%, a material loss of scale that erodes operating leverage. Such a sharp top‑line contraction makes fixed costs harder to cover, increases unit economics pressure, and lengthens the timeline to sustainable profitability absent a credible revenue recovery plan.
Negative Operating And Free Cash FlowPersistent negative operating and free cash flows indicate the business is burning cash and not self‑funding. Over several months this depletes runway, forces reliance on external financing or dilution, and constrains investments in R&D and commercialization critical for long‑term value creation.
Distressed Balance SheetNegative shareholders' equity signals liabilities exceed assets and denotes financial distress. This condition impairs borrowing capacity, can deter partners and suppliers, and raises the risk of restructuring or insolvency if operating cash flows do not improve in the medium term.
Vectus Biosystems Limited News
VBS FAQ
What was Vectus Biosystems Limited’s price range in the past 12 months?
Vectus Biosystems Limited lowest share price was AU$0.04 and its highest was AU$0.46 in the past 12 months.
What is Vectus Biosystems Limited’s market cap?
Vectus Biosystems Limited’s market cap is AU$8.28M.
When is Vectus Biosystems Limited’s upcoming earnings report date?
Vectus Biosystems Limited’s upcoming earnings report date is Aug 28, 2026 which is in 187 days.
How were Vectus Biosystems Limited’s earnings last quarter?
Currently, no data Available
Is Vectus Biosystems Limited overvalued?
According to Wall Street analysts Vectus Biosystems Limited’s price is currently Overvalued.
Does Vectus Biosystems Limited pay dividends?
Vectus Biosystems Limited does not currently pay dividends.
What is Vectus Biosystems Limited’s EPS estimate?
Vectus Biosystems Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vectus Biosystems Limited have?
Vectus Biosystems Limited has 53,433,330 shares outstanding.
What happened to Vectus Biosystems Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Vectus Biosystems Limited?
Currently, no hedge funds are holding shares in AU:VBS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vectus Biosystems Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
143.75%
12-Months-Change
Fundamentals
Return on Equity
-289.05%
Trailing 12-Months
Asset Growth
-61.36%
Trailing 12-Months
Company Description
Vectus Biosystems Limited
Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for fibrosis and high blood pressure, which include treatments for heart, kidney, liver, and lung diseases. Its lead compound is VB0004, which is aimed at treating the loss of functional tissue to fibrosis, scarring, and high blood pressure. The company also intends to develop candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis and pulmonary fibrotic diseases. In addition, it develops AccuCal and RealCount software that enhance speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories. The company was incorporated in 2005 and is based in Rosebery, Australia.